No Data
No Data
Privia Health Is Maintained at Equal-Weight by Barclays
Privia Health Is Maintained at Equal-Weight by Barclays
Barclays: Maintaining the Privia Health Gr (PRVA.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $22.00 to $19.00.
Barclays: Maintaining the Privia Health Gr (PRVA.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $22.00 to $19.00.
Barclays Maintains Equal-Weight on Privia Health Gr, Lowers Price Target to $19
Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:PRVA) with a Equal-Weight and lowers the price target from $22 to $19.
Privia Health Group (PRVA) Gets a Hold From Barclays
Privia Health Is Maintained at Buy by Truist Securities
Privia Health Is Maintained at Buy by Truist Securities
Truist Securities Adjusts Price Target on Privia Health Group to $24 From $28, Keeps Buy Rating
Privia Health Group (PRVA) has an average rating of buy and price targets ranging from $21 to $31, according to analysts polled by Capital IQ.